B. Riley Forecasts Stronger Earnings for Tango Therapeutics

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities researchers at B. Riley increased their FY2025 EPS estimates for shares of Tango Therapeutics in a research report issued on Monday, June 9th. B. Riley analyst Y. Zhi now expects that the company will post earnings of ($1.37) per share for the year, up from their previous forecast of ($1.49). The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics' FY2026 earnings at ($1.03) EPS.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). The business had revenue of $5.39 million for the quarter, compared to the consensus estimate of $6.73 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Monday, April 14th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $12.20.

Tango Therapeutics Stock Performance

NASDAQ TNGX traded down $0.42 on Thursday, reaching $4.63. The company had a trading volume of 1,924,110 shares, compared to its average volume of 1,472,724. The firm has a market capitalization of $502.19 million, a price-to-earnings ratio of -3.94 and a beta of 1.24. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $12.02. The company's fifty day moving average is $1.95 and its 200-day moving average is $2.41.

Hedge Funds Weigh In On Tango Therapeutics

A number of large investors have recently modified their holdings of TNGX. Deutsche Bank AG boosted its position in Tango Therapeutics by 24.1% during the fourth quarter. Deutsche Bank AG now owns 36,653 shares of the company's stock valued at $113,000 after purchasing an additional 7,128 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Tango Therapeutics in the 4th quarter valued at approximately $35,000. Northern Trust Corp boosted its holdings in shares of Tango Therapeutics by 7.1% in the 4th quarter. Northern Trust Corp now owns 513,079 shares of the company's stock valued at $1,585,000 after buying an additional 33,829 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Tango Therapeutics in the 4th quarter valued at approximately $771,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Tango Therapeutics in the fourth quarter valued at $1,599,000. 78.99% of the stock is currently owned by institutional investors and hedge funds.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.